NCT06588660View on ClinicalTrials.gov

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

February 14, 2025

Study Completion Date

February 14, 2025

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
BIOLOGICAL

Vevoctadekin

Given SC

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

OTHER

Medical Chart Review

Ancillary studies

DRUG

Teclistamab

Given SC

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Simcha Therapeutics
All Listed Sponsors
collaborator

Simcha Therapeutics

UNKNOWN

lead

University of Washington

OTHER

NCT06588660 - ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter